New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor)
Systemic lupus erythematosus (SLE) is a systemic autoimmune rheumatic disease of unknown etiology, characterized by overproduction of organ-specific autoantibodies to various components of the cell nucleus and the development of immune-inflammatory damage to internal organs. According to modern conc...
Saved in:
| Main Authors: | E. L. Nasonov, A. S. Avdeeva, T. V. Popkova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2021-10-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3072 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Portrait of a patient with systemic lupus erythematosus for the prescription of the type I interferon inhibitor anifrolumab
by: T. M. Reshetnyak, et al.
Published: (2023-12-01) -
Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)
by: T. M. Reshetnyak, et al.
Published: (2024-04-01) -
Adjunctive anifrolumab for recalcitrant discoid lupus erythematosus in the setting of systemic lupus erythematosus: A case report
by: Gabriela Soto-Canetti, MPH, et al.
Published: (2025-06-01) -
Flare of bullous lupus erythematosus in patients treated with anifrolumab for discoid lupus erythematosus: 2 cases
by: Cécile Lesort, MD, et al.
Published: (2025-04-01) -
Rapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report)
by: A. A. Baranov, et al.
Published: (2024-06-01)